Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

392 results about "Induced pluripotent stem cell" patented technology

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent."

Pluripotent stem cells obtained by non-viral reprogramming

Methods for reprogramming primate somatic cells to pluripotency using an episomal vector that does not encode an infectious virus are disclosed. Pluripotent cells produced in the methods are also disclosed.
Owner:WISCONSIN ALUMNI RES FOUND

Methods and compositions for the differentiation of stem cells

The present invention provides methods and compositions for the production of hematopoietic progenitor cells or endothelial progenitor cells from human pluripotent stem cells using a defined cell culture medium without the need to utilize feeder cells or serum. In some embodiments, differentiation is accomplished using hypoxic atmospheric conditions. The defined medium of the present invention may contain growth factors and a matrix component. The hematopoietic progenitor cells may be further differentiated into cell lineages including red blood cells, macrophages, granulocytes, and megakaryocytes. The endothelial progenitor cells may be further differentiated into endothelial cells. Also disclosed are screening assays for identification of candidate substances that affect differentiation of pluripotent stem cells into progenitor cells.
Owner:FUJIFILM CELLULAR DYNAMICS INC

Effective generation of tumor-targeted t cells derived from pluripotent stem cells

The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and / or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and / or 4) cytotoxic potential and anti-tumor activity.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same

Stem cell reprogramming genes cloned into a single sustained expression-type Sendai viral vector are shown to reprogram differentiated somatic cells into induced pluripotent stem (iPS) cells without integration of vector sequences into the host cell's genome. The genes are transduced into normal differentiated somatic cells via infection with recombinant Sendai virus. After expression of the reprogramming genes and subsequent induction of pluripotency, the vector genome RNA including the reprogramming genes is removed from the cell to establish an iPS cell that is genetically identical to the parent somatic differentiated cell thus reducing the risk of tumorigenic transformation caused by random integration of vector sequences into the host genome. The method promises to provide safe, autologous iPS cells that can be used for human cell replacement and regeneration therapeutic applications.
Owner:NAT INST OF ADVANCED IND SCI & TECH

Method of producing human retinal pigment epithelial cells

ActiveUS20130224156A1Stable of differentiationDegraded in termBiocideNervous system cellsDiseaseCulture cell
The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem cell into a pigment cell by adhesion cultivation of a human pluripotent stem cell in a medium containing a Nodal signal inhibitor and a Wnt signal inhibitor in the absence of a feeder cell to give a culture containing the pigment cell, (b) subjecting the obtained culture to further adhesion culture to give a culture containing a pigment cell colony, and (c) isolating the pigment cell from the obtained culture and culturing the cell to give a retinal pigment epithelial cell.
Owner:RIKEN

Pluripotent stem cell that can be isolated from body tissue

Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.
Owner:DEZAWA MARI +3

Compositions and methods for generation of pluripotent stem cells

The present invention describes the use of pre-trans-splicing molecules (PTMs) to reprogram human normal and diseased somatic cells into pluripotent stem cells using spliceosome-mediated RNA trans-splicing. More specifically, the present invention describes the use of the SMaRT™ technology to repair or reprogram the newly induced diseased pluripotent stem cells.
Owner:VIRXSYS

Method for reconstructing immune function using pluripotent stem cells

According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method; and a method for cell-based immunotherapy using the method.
Owner:THE UNIV OF TOKYO

Methods of Producing RPE Cells and Compositions of RPE Cells

The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
Owner:ADVANCED CELL TECH INC

Generation of cardiomyocytes from human pluripotent stem cells

Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND

Pluripotent stem cell-hereditary cardiomyopathy cardiac muscle cell and preparation method thereof

The invention belongs to the field of researching and application of biomedicine and particularly relates to human pluripotent stem cell-hereditary cardiomyopathy cardiac muscle cells and a preparation method thereof. The invention provides a human hereditary cardiomyopathy-pluripotent stem cell, which is constructed by means of TALEN or CRISPR / CAS9 genome editing technology. The human hereditary cardiomyopathy cardiac muscle cell can be combined with any scaffold materials to culture various in-vitro human hereditary cardiomyopathy cardiac muscle tissues. The human hereditary cardiomyopathy cardiac muscle cells in the invention have disease phenotypes and electrophysiology change being similar as the cardiac muscle cells of human hereditary cardiomyopathy patients. The human hereditary cardiomyopathy cardiac muscle cells are wide in sources and can be cultured in-vitro for a long time. The invention provides excellent tools and platforms for researching an effective new therapy means and researching an effective corresponding treatment medicine.
Owner:FUDAN UNIV

Cells and assays for use in detecting long qt syndrome

The present disclosure provides induced pluripotent stem (iPS) cells, and induced multipotent stem (iMS) cells, and progeny thereof, which cells include a gene encoding a polypeptide that regulates the QT interval. The present disclosure further provides panels of cardiomyocytes suitable for use in screening compounds for an effect on the QT interval. The cells and panels of cells can be used in a variety of applications, which are also provided.
Owner:THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS

Methods of generating pluripotent cells from somatic cells

Disclosed herein are methods to select for the generation of mouse and human pluripotent stem cells during developmental reprogramming. The methods described herein relate to the selection of induced pluripotent stem cells, i.e., pluripotent stem cells generated or induced from differentiated cells without a requirement for genetic selection. Described herein are particular embodiments for selection of reprogrammed cells based on 1) colony morphology, or 2) X chromosome reactivation in female cells.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Method for preparing evoked pluripotent stem cell

The invention provides a method for preparing induced embryonic stem cells, which comprises following steps: firstly, introducing six transcription factors into adult cells, secondly, culturing the adult cells under the condition for culturing the embryonic stem cells, and enabling the adult cells to form cells with the form of embryonic stem cells. The method of the invention also comprises: cloning the six transcription factors into a carrier and then transforming the six transcription factors into the adult cells. When the method of the invention is adopted to prepare the embryonic stem cells, the efficiency is high, the acute rejection can be avoided, the embryonic stem cells can be differentiated into different tissue cells under special conditions, and the method of the invention has wide applying prospect.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI

Exosome derived from human pluripotent stem cells, preparation based on exosome and use of exosome and preparation

The invention relates to an exosome derived from human pluripotent stem cells, a preparation based on the exosome and use of the exosome and preparation, and belongs to the technical fields of cell biology, molecular biology and drug research and development. The human pluripotent stem cell exosome or the preparation based on the human pluripotent stem cell exosome has the uses of A, being an additive cultured in vitro for maintaining the stemness of adult stem cells and inhibiting the senility of the adult stem cells; B, being an additive cultured in vitro for maintaining the proliferative activity of various tissue primary culture cells; C, being applied in preparing medicine for treating bone and cartilage degenerative changes; D, being applied in preparing medicine for preventing the bone and cartilage degenerative changes; E, being applied in preparing medicine for treating orthopedic diseases such as osteonecrosis, bone nonunion, fractures, cartilage injuries, tendon injuries, frozen shoulders or tendon adhesion. Compared with the prior art, the exosome secreted by the pluripotent stem cells has powerful functions of promoting tissue cell regeneration, preventing senility andtreating bone diseases.
Owner:上海睿泰生物科技股份有限公司

Method for obtaining hemopoietic stem cell by using three-dimensional induction system

The invention provides a method for obtaining a hemopoietic stem cell by using a three-dimensional induction system. A three-dimensional cell culture medium or cell culture bracket, such as a three-dimensional cell culture system made of the materials such as hydrogel, seaweed and the like is utilized, and / or combined with matrix cells such as bone marrow cell, mouse bone marrow cell lines OP9, OP9DL1 and the like, and / or combined with a plurality of factors including mesoderm induction factors, hematopoietic growth factor and the like to induce multipotent stem cells to differentiate into hemopoietic stem cells. A new method for obtaining the hemopoietic stem cells is built. The system for efficiently inducing the multipotent stem cells to differentiate into the hemopoietic stem cells by using a three-dimensional induction system and / or combining with matrix cells such as bone marrow cell and the like and / or a plurality of factors is built for the first time. Theoretical basis and a technology platform are provided for obtaining clinically available hemopoietic stem cells, and a new method and a new concept are developed for application of hematopoietic cells derived from multipotent stem cells in the fields such as disease mechanism exploration, drug screening and the like.
Owner:ZHEJIANG UNIV

Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof

Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E2 pathway stimulants, TPO, SCF, FLT-3, EPO, TGFβ1, p38 MAPK inhibitors, beta adrenergic receptor agonists, cell cycle inhibitors, RXR agonists, Cripto, and chromatin remodelers to drive differentiation of pluripotent stem cells towards primitive blood cells. Uses of such primitive blood cells are provided.
Owner:NUCLEUS BIOLOGICS LLC

Methods of producing rpe cells and compositions of rpe cells

The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
Owner:ADVANCED CELL TECH INC

Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells

The present application describes the new methods for the differentiation of primate pluripotent stem cells into cardiomyocyte-lineage cells. The methods utilize sequential culturing of the primate pluripotent stem cells in certain growth factors to produce cardiomyocyte-lineage cells. In certain embodiments of the invention, the population of cells produced by the sequential culturing is further enriched for cardiomyocyte-lineage cells so as to produce a higher percentage of those cells.
Owner:ASTERIAS BIOTHERAPEUTICS INC

Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures

Provided herein are methods for the generation of functional keratinocyte stem cells that are differentiated directly from human ESCs / iPSCs in a chemically defined serum-free cell culture system, as well as cells derived therefrom and methods of use thereof. Also provided are methods for culturing primary keratinocytes.
Owner:FUJIFILM CELLULAR DYNAMICS INC

Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same

Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+ progenitors, and then to 04+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, 04+ OPCs are able to differentiate into MBP+ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.
Owner:NEW YORK STEM CELL FOUND

Reprogrammed culture medium and culture method of reprogrammed induced multipotential stem cell

The invention relates to a reprogrammed culture medium and a culture method of a reprogrammed induced multipotential stem cell. The reprogrammed culture medium is composed of a DMEM-F12 basal culturemedium and additive components, wherein the additive components comprise 60-180 microgram / mL of L-ascorbic acid, 5.3-74 micromole / L of hydrocortisone, 3-89 nanogram / mL of sodium selenite, 8-23 micromole / L of Optiferrin, 0.5-7.4 micromole / L of retinyl acetate, 40-60 nanogram / mL plant-derived recombinant human alkaline growth factors, 8-12 microgram / mL of IGF, 0.2-0.6 microgram / mL A-83, 2-6 micromole / L of CHIR99021 and 100-450 micromole / L of sodium butyrate. The use of the reprogrammed culture medium not only can improve the safety of clinical use, but also can improve the efficiency of adult cell reprogramming to induce the multipotential stem cell.
Owner:IREGENE THERAPEUTICS LTD

Preparation for treating heart disease used in cell therapy

An object of the present invention is to establish a cell transplantation method which can markedly improve the survival of grafted pluripotent stem cells and the efficiency of cardiomyocyte regeneration in cell therapy using pluripotent stem cells derived from heart tissue and can treat heart disease further effectively. Specifically, according to the present invention, enhancement in the survival of grafted pluripotent stem cells and significant improvement in the efficiency of cardiomyocyte regeneration are achieved by using, in combination, pluripotent stem cells derived from heart tissue and a hydrogel containing a basic fibroblast growth factor (bFGF) in cell therapy for heart disease.
Owner:KYOTO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products